Shilpa Johri, MD
Pulmonary Disease · Richmond, VANPI 1275511719
Payments from drug & device makers
Across 853 payments — averaging $1975.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$810K
- United Therapeutics Corporation$665K
- Bayer$67K
- Janssen Research & Development, LLC$54K
- Boehringer Ingelheim$45K
- Boehringer Ingelheim International GmbH$15K
- plus $29K from 32 others
Across 15 payments — averaging $104.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 53 | $809,863 |
| United Therapeutics Corporation | 213 | $665,027 |
| Bayer | 49 | $67,105 |
| Janssen Research & Development, LLC | 15 | $53,872 |
| Boehringer Ingelheim | 53 | $45,237 |
| Boehringer Ingelheim International GmbH | 25 | $14,522 |
| Actelion Pharmaceuticals US, Inc. | 67 | $12,420 |
| Novartis | 16 | $10,643 |
| GSK | 142 | $1,472 |
| AstraZeneca | 36 | $991 |
| Grifols USA, LLC | 18 | $412 |
| Sanofi | 22 | $410 |
| Amgen | 21 | $384 |
| Genentech USA, Inc. | 20 | $335 |
| Mallinckrodt Hospital Products Inc. | 11 | $309 |
| Regeneron Healthcare Solutions, Inc. | 16 | $288 |
| Insmed, Inc. | 17 | $272 |
| ANI Pharmaceuticals, Inc. | 7 | $202 |
| Chiesi USA, Inc. | 1 | $132 |
| Pfizer | 7 | $130 |
| Novo Nordisk | 1 | $124 |
| Mylan Specialty L.p. | 7 | $103 |
| Electromed, Inc. | 8 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $84 |
| Gilead | 5 | $75 |
| Sunovion Pharmaceuticals Inc. | 3 | $63 |
| Baxter Healthcare | 3 | $58 |
| Pulmonx Corporation | 2 | $53 |
| Mallinckrodt Enterprises LLC | 2 | $32 |
| Atricure, Inc. | 1 | $26 |
| 3b Medical, Inc. | 1 | $23 |
| Inogen, Inc. | 1 | $22 |
| Viatris Specialty LLC | 1 | $16 |
| Philips North America LLC | 1 | $16 |
| Verona Pharma, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Sandoz | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
How this compares
$1,684,857 in reported general payments places this provider in the 95th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Richmond
- Patricia SimeRichmond$572K
- Apostolos PerelasRichmond$567K
- Ray ShepherdRichmond$303K
- Sujoy GillRichmond$296K
- Glenn GiesselRichmond$267K
- Marjolein DewitRichmond$214K
- Nauman ChaudaryRichmond$77K
- Ritsu KunoRichmond$64K
- Daniel GrinnanRichmond$45K
- Kenneth HaftRichmond$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.